FIT-CD19 CAR-T / TriArm Therap - LARVOL DELTA

Rapid Manufacture and Effective Response of FIT-CD19 CAR-T in Relapsed B-ALL: A Case from NTUH (EHA-EBMT-CART 2026) - P1 | "After infusion (3×10⁴ CAR-T/kg), she developed grade 1 CRS resolved with one dose of tocilizumab and grade 1 ICANS that resolved spontaneously; no trial defined dose-limiting toxicities occurred. CAR-T expansion peaked on Day 10–11, comparable to established Tisagenlecleucel kinetics...These findings underscore the potential of this new technique to significantly improve accessibility and timely delivery of CAR-T therapy, particularly for patients in urgent need. Clinical Trial Registry : Study Details NCT07066397 A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL ClinicalTrials.gov"

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: TriArm Therapeutics (Taiwan) Limited

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

TriArm Therapeutics develops FIT-CD19 CAR-T therapy and receives IND approval from FDA (money.udn.com) - "The innovative Fast-in-time CAR-T cell therapy developed by TriArm Taiwan-Tron Biotech Co., Ltd. has successfully obtained approval from the U.S. Food and Drug Administration (FDA) on October 19, 2023, allowing the the therapy enters clinical trials. Bringing a new dawn to patients with non-Hodgkin lymphoma around the world....Fast-in-time CAR-T cell therapy is a self-developed, patented, non-viral genetically modified T cell."

IND • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology